120 related articles for article (PubMed ID: 28378597)
1. Preparation of intravenous injection nanoformulation via co-assemble between cholesterylated gemcitabine and cholesterylated mPEG: enhanced cellular uptake and intracellular drug controlled release.
Xu Y; Zhong X; Zhang X; Lv W; Yu J; Xiao Y; Liu S; Huang J
J Microencapsul; 2017 Mar; 34(2):185-194. PubMed ID: 28378597
[TBL] [Abstract][Full Text] [Related]
2. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
4. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
5. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer.
Liang TJ; Zhou ZM; Cao YQ; Ma MZ; Wang XJ; Jing K
Int J Pharm; 2016 Nov; 513(1-2):564-571. PubMed ID: 27613255
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of gemcitabine and cisplatin via Poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) micelle to improve the in vivo stability and antitumor effect.
Ding N; Zhao Z; Yin N; Xu Y; Yin T; Gou J; He H; Wang Y; Zhang Y; Tang X
Pharm Res; 2021 Dec; 38(12):2091-2108. PubMed ID: 34893950
[TBL] [Abstract][Full Text] [Related]
8. A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-
Sun Y; Wang J; Hao K
Molecules; 2020 May; 25(9):. PubMed ID: 32397338
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
Gontero P; Cattel L; Paone TC; Milla P; Berta G; Fiorito C; Carbone F; Medana C; Tizzani A
BJU Int; 2010 Dec; 106(11):1652-6. PubMed ID: 20590553
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.
Limmer S; Hahn J; Schmidt R; Wachholz K; Zengerle A; Lechner K; Eibl H; Issels RD; Hossann M; Lindner LH
Pharm Res; 2014 Sep; 31(9):2276-86. PubMed ID: 24599802
[TBL] [Abstract][Full Text] [Related]
11. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
12. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
13. Tailoring the properties of mPEG-PLLA nanoparticles for better encapsulation and tuned release of the hydrophilic anticancer drug.
Surwase SS; Munot NM; Idage BB; Idage SB
Drug Deliv Transl Res; 2017 Jun; 7(3):416-427. PubMed ID: 28324320
[TBL] [Abstract][Full Text] [Related]
14. Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate.
Chu W; Tian P; Ding N; Cai Q; Li J; Zhuo X; Tang Z; Gou J; Yin T; Zhang Y; He H; Tang X
Pharm Res; 2018 Oct; 35(12):230. PubMed ID: 30327887
[TBL] [Abstract][Full Text] [Related]
15. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
[TBL] [Abstract][Full Text] [Related]
16. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer.
Vandana M; Sahoo SK
Biomaterials; 2010 Dec; 31(35):9340-56. PubMed ID: 20851464
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.
Naguib YW; Lansakara-P D; Lashinger LM; Rodriguez BL; Valdes S; Niu M; Aldayel AM; Peng L; Hursting SD; Cui Z
Neoplasia; 2016 Jan; 18(1):33-48. PubMed ID: 26806350
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
19. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
20. Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles.
Jia L; Zheng JJ; Jiang SM; Huang KH
World J Gastroenterol; 2010 Feb; 16(8):1008-13. PubMed ID: 20180242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
